Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Arikayce is a prescription amikacin liposome inhalation suspension used for refractory Mycobacterium avium complex lung disease in a limited adult population. It is added to a combination antibacterial regimen for patients with limited or no alternative treatment options who have not achieved negative sputum cultures after at least six consecutive months of multidrug background therapy.
read more about arikayce ...Amikacin is an aminoglycoside antibacterial that binds to the bacterial 30S ribosomal subunit and disrupts protein synthesis. Arikayce encloses amikacin in liposomes for delivery to the lungs by inhalation. The formulation exposes affected airways to amikacin while systemic blood concentrations remain lower than those seen with intravenous amikacin dosing.
Arikayce is reserved for adults with refractory Mycobacterium avium complex lung disease who have limited or no alternative treatment options. The labeled population has failed to achieve negative sputum cultures after at least six consecutive months of a multidrug background regimen. Arikayce is not recommended for non-refractory MAC lung disease.
The recommended dose is one 590 mg per 8.4 mL vial inhaled once daily through the Lamira Nebulizer System. The vial is brought to room temperature and shaken before use. Arikayce is for oral inhalation only and is not injected. If a dose is missed, the next dose is taken the following day without doubling.
Arikayce carries a boxed warning for increased respiratory adverse reactions, including hypersensitivity pneumonitis, coughing up blood, bronchospasm, and worsening underlying lung disease. Other serious risks include anaphylaxis, hearing or balance toxicity, kidney toxicity, neuromuscular blockade, and fetal harm. Aminoglycoside hypersensitivity is a contraindication.
Yes. Arikayce contains amikacin, an aminoglycoside antibacterial formulated in liposomes for inhalation into the lungs.
The labeled adult dose is one 590 mg vial inhaled once daily through the Lamira Nebulizer System.
No. It is reserved for refractory MAC lung disease in adults with limited or no alternative treatment options.
No. Arikayce is for oral inhalation through the Lamira Nebulizer System and should not be injected.
Amikacin Oral Inhalation. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623020.html. Date Accessed September 14, 2026.
ARIKAYCE (amikacin liposome inhalation suspension) Medication Guide. https://www.arikayce.com/pdf/medication-guide.pdf. Date Accessed September 14, 2026.
ARIKAYCE (amikacin liposome inhalation suspension) Prescribing Information. https://www.arikayce.com/pdf/full_prescribing_information.pdf. Date Accessed September 14, 2026.
DailyMed - ARIKAYCE (amikacin liposome inhalation suspension). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=499ab990-2b21-474f-aaba-d86388965f40. Date Accessed September 14, 2026.
Lamira Nebulizer System Instructions for Use. https://www.arikayce.com/pdf/instructions_for_use.pdf. Date Accessed September 14, 2026.